ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

ProQR Therapeutics N.V.NASDAQ: PRQR

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to €0

Q1 FY2026 stock-based compensation was €0, compared with €758K a year earlier. Trailing-twelve-month stock-based compensation was €2.03M.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 13.5 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near €0 or moves back toward the trailing-twelve-month quarterly average of €506.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€0— QoQ
Last fiscal yearDec 2025
€0-100.0% YoY
LTMMar 2026
€2.03M-21.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

EUR · from the cash flow

Latest · FY2025
0 EUR
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -21.0% is the 5th highest of 11, against a peer median of -28.3%.
  • Stock-based compensation amounts to 15.1% of revenue for PRQR, versus a peer median of 37.2%.
PRQR Competitors
Stock-Based Compensation for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$3.98B USD+32410.1%+56.9%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.74M USD-35.1%-23.4%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$23.07M USD-33.2%-6.0%50.9%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$19.27M USD-0.0%+25.6%335.8%
ZURAZura Bio LimitedLTM Mar 2026$11.32M USD-37.2%+233.0%—
EDITEditas Medicine, Inc.LTM Mar 2026$9.12M USD-45.7%-30.1%23.6%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$9.07M USD-23.3%-16.5%4.2%
MREOMereo BioPharma Group plcLTM Mar 2026$6.93M USD-9.1%+16.8%1385.0%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$5.84M USD-6.8%+38.9%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.03M EUR-21.0%—15.1%
IMMPImmutep LimitedFY2025A$1.16M AUD-35.2%-7.8%23.1%
Peer median (excluding PRQR) —-28.3%+5.4%37.2%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(60.8M)(64.2M)(27.74M)(27.76M)(40.52M)
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
Deferred Income Tax117K96K(78K)(197K)0
Stock-Based Compensation6.22M2.87M3.11M2.54M0
Change in Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Other Non-Cash Items1.11M(4.8M)(5.21M)(474K)3.94M
Operating Cash Flow(26.01M)(68.51M)21.55M(36.39M)(50.71M)
Capital Expenditures(484K)(708K)(1.37M)(1.42M)(979.75K)
Acquisitions (Net)00000
Purchases of Investments000(17M)0
Sales of Investments00017M0
Other Investing Activities59K6K5.65M(2.66M)0
Investing Cash Flow(425K)(702K)4.28M(4.07M)(979.74K)
Debt Repayment26.84M(45.05M)(2.63M)(1.58M)(1.91M)
Common Stock Issued108.48M14.12M071.64M66.28K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.52M34K354K223K75.19K
Financing Cash Flow136.83M(30.89M)(2.28M)70.28M(1.76M)
Effect of Forex Changes1.29M7.35M599K673K14.15M
Net Change in Cash111.69M(92.75M)24.15M30.48M(39.3M)
Free Cash Flow(26.5M)(69.22M)20.18M(37.81M)(51.69M)

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.